Major Challenges Facing Immunotherapy Developers

  

Dr. Marc Better, Vice President of Product Sciences, Kite Pharma - a Keynote Speaker at this years Cell Therapy Bioprocessing & Commercialization Event, sat down to discuss the current projects he is working on at Kite Pharma, the biggest challenges facing immunotherapy developers, regulatory hurdles, and this years meeting. Below you will find a brief teaser from the interview, to access the full interview, follow the links below...

Podcast | Transcript

What are the biggest challenges facing immunotherapy developers?

Well really, I think the biggest challenge for us is that we are charting new ground. There really isn’t a lot of precedent for bringing this type of product to the market. However, we do know - at least in the early trials we are seeing really exciting results both with our collaborators at the NCI and other institutions. We are building a lot of processes and systems around this to allow us to expand these programs and commercialize products like KTC 19.

Any field that is as innovative and exciting as this is very challenging, but we are very committed to being the best in the area that we can possibly be....[Click here to continue reading] 


Want to hear more from Dr. Better? Join him in Alexandria, VA for Cell Therapy Bioprocessing & Commercialization, September 30 - October 2, 2015 - where Dr. Better will have a keynote address titled "Overcoming Challenges for Engineered Autologous T-Cell Therapy". To see the complete agenda, click here. And register now with the code XB15188BLOG to save $100 off the current rate.

See you in Alexandria!

Share this article with your social network, just click below to share now!

Share |